Better Life Through Better Science
KaloBios is developing a robust proprietary portfolio of customized, targeted, first-in-class monoclonal antibodies designed to significantly improve the care of seriously ill patients with difficult to treat diseases.
Recent Corporate Highlights
- Raised $70 million in an initial public offering
- Phase 2 study was initiated with KB003 Humaneered® monoclonal antibody in severe athsma.
- Phase 1 clinical trial was initiated for KB004
- KaloBios partnered with Sanofi Pasteur for KB001-A in hospital indications.